Inactive Instrument

Highlights Momenta Pharmaceuticals, Inc.

Equities

MNTA

US60877T1007

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Johnson & Johnson completed the acquisition of Momenta Pharmaceuticals, Inc..	20-09-30	CI
Johnson & Johnson : J&J, Biotech Firm In $6.5 Billion Deal J&J Agrees to Buy Biotech Company	20-08-20	DJ
Johnson & Johnson : to Buy Momenta Pharmaceuticals for $6.5 Billion	20-08-19	DJ
Johnson & Johnson entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. for $6.3 billion.	20-08-18	CI
Janssen Pharmaceuticals, Inc. agreed to acquire Pipeline Of Clinical and Pre-Clinical Assets of Momenta Pharmaceuticals, Inc..	20-08-18	CI
Momenta Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-10	CI
Momenta Pharmaceuticals, Inc. Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN	20-07-28	CI
Momenta Pharmaceuticals, Inc. Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab	20-06-15	CI
Momenta Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-07	CI
Momenta Pharmaceuticals, Inc. Provides an Update on the Company’S Clinical Trial Activities and Business Operations in Light of the COVID-19 Pandemic	20-04-02	CI
Momenta Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	20-02-26	CI
Momenta Pharmaceuticals, Inc. Provides 2019 Year-End Corporate Update and Key Anticipated Milestones for 2020	20-01-13	CI
Momenta Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-10-31	CI
Momenta Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-02	CI
Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and Is Granted FDA Fast Track Designation	19-08-01	CI
Momenta Pharmaceuticals Announces Fast Track Designation for M281 in Hemolytic Disease of the Fetus and Newborn	19-07-30	CI
Amphastar Pharmaceuticals, Inc. Announces Settlement in Litigation with Momenta and Sandoz	19-06-19	CI
Momenta Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-02	CI
Momenta Pharmaceuticals, Inc. Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta	19-03-21	CI
Momenta Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2018	19-02-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Momenta Pharmaceuticals, Inc.

Equities

MNTA

US60877T1007

Highlights

Filters